Similar articles

• Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease.

  LeWitt PA. LeWitt PA. JAMA Neurol. 2020 Aug 1;77(8):1038-1039. doi: 10.1001/jamaneurol.2020.1928. JAMA Neurol. 2020. PMID: 32597929 No abstract available.
• Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.

  Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C. Pagan FL, et al. JAMA Neurol. 2020 Mar 1;77(3):309-317. doi: 10.1001/jamaneurol.2019.4200. JAMA Neurol. 2020. PMID: 31841599 Free PMC article. Clinical Trial.
• Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.

  Goldstein DS, Holmes C, Lopez GJ, Wu T, Sharabi Y. Goldstein DS, et al. Parkinsonism Relat Disord. 2018 May;50:108-112. doi: 10.1016/j.parkreldis.2018.02.023. Epub 2018 Feb 15. Parkinsonism Relat Disord. 2018. PMID: 29475591 Free PMC article.
• Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.

  Marek K, Jennings D, Seibyl J. Marek K, et al. Neurology. 2003 Sep 23;61(6 Suppl 3):S43-8. doi: 10.1212/wnl.61.6_suppl_3.s43. Neurology. 2003. PMID: 14504379 Review. No abstract available.
• 5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.

  Badillo-Ramírez I, Saniger JM, Rivas-Arancibia S. Badillo-Ramírez I, et al. Neurochem Int. 2019 Oct;129:104514. doi: 10.1016/j.neuint.2019.104514. Epub 2019 Jul 29. Neurochem Int. 2019. PMID: 31369776 Review.